Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of CAR T cell treatment
targeting CD7 in patients with relapsed or refractory CD7 positive T-cell hematological
maliganacies
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine